Tolerability of Capsaicinoids fromCapsicumExtract in a Beadlet Form: A Pilot Study
Authors:
Open Access
- 15 March 2016
- journal article
- research article
- Published by Hindawi Limited in Journal of Toxicology
- Vol. 2016, 1-8
Abstract
A single center, open-label, dose-finding adaptive study was conducted in twelve healthy overweight female subjects. The study was to evaluate the safety and tolerability of the capsaicinoids (CAPs) from Capsicum extract in a beadlet form compared to placebo in a healthy overweight population. The investigational product capsaicinoids (CAPs) from Capsicum extract in a beadlet form (Capsimax®) a proprietary encapsulated form of Capsicum extract in beadlet form supplemented at 2mg, 4mg, 6mg, 8mg and 10mg of CAPs. An ascending dose protocol evaluated a total dose of 10mg daily given in five divided doses (2mg, 4mg, 6mg, 8mg and 10mg of CAPs). Each dose was given for a week. Safety and tolerability were assessed. Primary outcomes were tolerability assessments and reports of adverse events. Tolerability assessments were observed on skin color and any changes in skin, bowel movement, digestion, mouth or throat, hair color or changes in hair color, urination includes frequency and burning sensations, breathing, any changes in their health. Secondary outcomes were body weight, body mass index (BMI), blood pressure (SBP/DBP), vital signs, electrocardiograms, clinical chemistry parameters including liver function tests, lung function tests and kidney function tests and complete blood count (CBC). No dose effective changes were observed. The escalating dose levels of CAPs in a beadlet form product found was tolerable and safe for weight management studies. Tolerability assessments and safety blood markers showed no significant changes from baseline. No significant serious adverse events were reported throughout the duration of the study. Further longer term studies are required to explore the tolerability of the product. This trial is registered with ISRCTN: #ISRCTN10975080. A single center, open-label, dose-finding adaptive study was conducted in twelve healthy overweight female subjects. The study was to evaluate the safety and tolerability of the capsaicinoids (CAPs) from Capsicum extract in a beadlet form compared to placebo in a healthy overweight population. The investigational product capsaicinoids (CAPs) from Capsicum extract in a beadlet form (Capsimax®) a proprietary encapsulated form of Capsicum extract in beadlet form supplemented at 2mg, 4mg, 6mg, 8mg and 10mg of CAPs. An ascending dose protocol evaluated a total dose of 10mg daily given in five divided doses (2mg, 4mg, 6mg, 8mg and 10mg of CAPs). Each dose was given for a week. Safety and tolerability were assessed. Primary outcomes were tolerability assessments and reports of adverse events. Tolerability assessments were observed on skin color and any changes in skin, bowel movement, digestion, mouth or throat, hair color or changes in hair color, urination includes frequency and burning sensations, breathing, any changes in their health. Secondary outcomes were body weight, body mass index (BMI), blood pressure (SBP/DBP), vital signs, electrocardiograms, clinical chemistry parameters including liver function tests, lung function tests and kidney function tests and complete blood count (CBC). No dose effective changes were observed. The escalating dose levels of CAPs in a beadlet form product found was tolerable and safe for weight management studies. Tolerability assessments and safety blood markers showed no significant changes from baseline. No significant serious adverse events were reported throughout the duration of the study. Further longer term studies are required to explore the tolerability of the product. This trial is registered with ISRCTN: #ISRCTN10975080.Keywords
This publication has 34 references indexed in Scilit:
- Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and womenJournal of the International Society of Sports Nutrition, 2013
- Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months’ consumption of a combination of bioactive food ingredients in overweight subjectsEndocrine, 2012
- Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat PainPharmacological Reviews, 2012
- The Effects of Capsaicin and Capsiate on Energy Balance: Critical Review and Meta-analyses of Studies in HumansChemical Senses, 2011
- Dietary Capsaicin Attenuates Metabolic Dysregulation in Genetically Obese Diabetic MiceJournal of Medicinal Food, 2011
- Effect of oral intake of capsaicinoid beadlets on catecholamine secretion and blood markers of lipolysis in healthy adults: a randomized, placebo controlled, double-blind, cross-over studyLipids in Health and Disease, 2010
- Acute Effects of a Thermogenic Nutritional Supplement on Energy Expenditure and Cardiovascular Function at Rest, During Low-Intensity Exercise, and Recovery from ExerciseJournal of Strength & Conditioning Research, 2009
- The acute effects of a lunch containing capsaicin on energy and substrate utilisation, hormones, and satietyEuropean Journal of Nutrition, 2009
- Intramuscular lipid metabolism, insulin action, and obesityIUBMB Life, 2008
- Induction of Apoptosis in Leukemic Cells by Homovanillic Acid Derivative, Capsaicin, through Oxidative StressCancer Research, 2004